Abstract
Immunotherapy (IT) targeting programmed cell death-1 receptor (PD-1) and programmed death-ligand 1 (PD-L1) has considerably improved the overall survival of non-small cell lung cancer (NSCLC) patients. This network meta-analysis (MA) evaluates the safety of first-line (1L) PD-L1 inhibitors monotherapy in advanced NSCLC patients compared to platinum-based chemotherapy (CT). We also compared the risk of Adverse Events (AEs) according to programmed cell death-1 receptor (PD-1) or PD-L1 inhibitors therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
